[New strategies for BMT]

Using various autoimmune-prone mice, we have previously shown that conventional allo BMT can be used to treat a range of autoimmune diseases. These findings have recently been confirmed even in humans. However, in humans, the success rate of BMT across major histocompatibility complex(MHC) barriers is lowered by graft-versus-host disease(GvHD), graft rejection, and incomplete T-cell recovery. We have just established a new BMT method in which bone marrow cells(BMCs) are directly injected into the intra-bone marrow(IBM-BMT). We here show that 'IBM-BMT' is the best strategy for allo BMT and also organ allografts to induce persistent tolerance.